Biomedical Advanced Research and Development Authority (BARDA)
330 C Street, SW
Room G640
Washington
D.C.
20201
United States
Tel: 202-260-1200
Fax: 202-205-4520
237 articles about Biomedical Advanced Research and Development Authority (BARDA)
-
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
3/5/2024
RedHill Biopharma Ltd. together with its partner Apogee Biotechnology Corporation, announced that opaganib[2] has been selected by the U.S. government's Chemical Medical Countermeasures Program and Chemical Countermeasures Research Program for evaluation as a potential medical countermeasure against inhalation Sulfur Mustard exposure.
-
HDT Bio Receives $749,000 EZBAA Contract and Partners with BARDA Under Project NextGen's Enabler's Program
1/23/2024
HDT Bio Corp. today announced that it has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, under Project NextGen's Enabler's program.
-
Locus Biosciences Announces $23.9 Million in Funding from BARDA to Support First Phase 2 Trial of CRISPR-engineered Bacteriophage Therapy
1/23/2024
Locus Biosciences, Inc. today announced the release of $23.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to continue the development of Locus’ CRISPR-enhanced bacteriophage therapy, LBP-EC01, for treating urinary tract infections (UTIs) caused by drug-resistant Escherichia coli (E. coli) based on positive results from a Phase 2a clinical trial.
-
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
1/19/2024
Vaxart, Inc. (Nasdaq: VXRT) today announced that the United States Biomedical Advanced Research and Development Authority (BARDA) has awarded the Company $9.27 million to fund preparation for a 10,000 subject Phase 2b clinical study evaluating Vaxart’s oral pill XBB COVID-19 vaccine candidate against an approved mRNA vaccine comparator.
-
ATCC Announces New Award from BARDA to Provide Centralized Storage and Bioprocessing Services for Project NextGen
1/4/2024
ATCC today announced a five-year, $87 million award from the Biomedical Advanced Research and Development Authority ( BARDA ), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support the development of next-generation medical countermeasures (MCMs) to protect Americans from public health security threats such as coronaviruses.
-
Battelle Part of Team Selected to Support New Technologies to Prepare for Future COVID-19 Outbreaks
11/8/2023
As part of the federal $5 billion Project NextGen program, Battelle was awarded $6.1 million from the BARDA to advance human lung and airway tissue chip platform technology, also known as “organ on a chip.” The award is part of BARDA’s indefinite delivery/indefinite quantity contract with Battelle.
-
BARDA Expands Partnership With Evidation to Validate and Improve Machine Learning Models for Early Detection of Influenza-like Illness Using Wearables
10/17/2023
Evidation announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to fund the 2023 Influenza-like Illness Detect & Protect Studies.
-
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
10/16/2023
BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce a second partnership with the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.
-
GE HealthCare Signs $44 Million Contract with BARDA to Develop Artificial Intelligence-Augmented Ultrasound Technology to Aid Clinicians in Diagnosing and Treating Traumatic Injury and Enhance National Preparedness for Mass Casualty Incidents
10/12/2023
GE HealthCare announced it signed a $44 million contract with the Biomedical Advanced Research and Development Authority —part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services —to develop and obtain regulatory clearance for next-generation advanced point-of-care ultrasound technology with new artificial intelligence applications.
-
Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract
10/10/2023
Venatorx Pharmaceuticals today announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has awarded the company a contract to support the development of oral ceftibuten-ledaborbactam etzadroxil for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.
-
Codagenix Announces BARDA Contract for Project NextGen Supporting Development of CoviLiv™ as an Intranasal COVID-19 Vaccine
10/3/2023
Codagenix Inc. announced that the BARDA has entered into a contract with Codagenix to support the costs of a Phase 2b clinical study of CoviLiv™ for the prevention of symptomatic COVID-19 in people who have completed their primary approved/authorized COVID-19 vaccine series and their last COVID-19 vaccine was at least 3 months beforehand.
-
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
10/3/2023
Vir Biotechnology, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, has awarded Vir approximately $50 million in new funding to advance the development of novel monoclonal antibody candidates and delivery solutions to widen the applicability of mAbs in COVID-19 and in pandemic preparedness and response.
-
ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats
9/28/2023
ModeX Therapeutics Inc., an OPKO Health, Inc. company, has been awarded a contract from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, to advance a platform and specific candidates designed to address a range of public health threats in viral infectious diseases.
-
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
9/27/2023
Gritstone bio, Inc. announced that it was awarded a contract by the Biomedical Advanced Research and Development Authority to conduct a Phase 2b comparative study evaluating Gritstone’s self-amplifying mRNA vaccine candidate containing Spike plus other viral targets to protect against COVID-19.
-
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
9/27/2023
MediciNova, Inc. announced the results of the nonclinical studies conducted under its contract with the BARDA, part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services, to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury.
-
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
9/13/2023
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces that it is partnering with the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to execute a clinical trial to evaluate the effectiveness of next generation COVID-19 vaccine candidates.
-
Satio partners with BARDA DRIVe to develop a novel patch-based ebolavirus diagnostic
8/18/2023
Satio is pleased to announce a contract awarded by the Biomedical Advanced Research and Development Authority ( BARDA ), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to develop a novel, single-use, rapid ebolavirus diagnostic.
-
Cue Health Awarded New $28 Million Federal Contract to Develop Flu A/B, RSV, COVID-19 Molecular Multiplex Test for Both Over-the-Counter and Point-of-Care Use
8/3/2023
Cue Health announced that it has been awarded a new approximately $28 million contract by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to develop a Flu A/B, RSV, and COVID-19 molecular multiplex test for both over-the-counter and point-of-care use.
-
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
8/3/2023
Bavarian Nordic A/S announced that the U.S. Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, has placed a new order valued at USD 120 million, primarily covering the manufacturing of new bulk product for the Company’s smallpox/mpox vaccine.
-
RIVANNA receives $30.5 million from BARDA to advance the Accuro XV musculoskeletal imaging system
7/28/2023
RIVANNA®, developers of imaging-based medical solutions, announced that they have received funding totaling $30.5 million over 39 months from early execution of an option by the Biomedical Advanced Research